Ram I. Mahato is Parke-Davis Endowed Professor and Chairman of the Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE. He was a professor at the University of Tennessee Health Science Center in Memphis, Research Assistant Professor at the University of Utah in Salt Lake City, Senior Scientist at GeneMedicine, Inc., The Woodlands, TX, and as a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He received PhD in Drug Delivery from the University of Strathclyde and BSPS from China Pharmaceutical University. He has published 168 papers, 17 book chapters, holds 4 US patents, and has edited/written 12 books and 14 journal issues (Total Google Citations= 14,609 and h-Index =70). He was a Feature Editor of the Pharmaceutical Research (2006-2013) and Editorial Board Member of eight journals. He is a CRS and AAPS Fellow, Permanent Member of BTSS/NIH Study section, and ASGCT Scientific Advisor. He is applying sound principles in pharmaceutical sciences in the context of the latest advances in life and material sciences to solve challenging drug delivery problems in therapeutics.Ajit S. Narang works as a Vice President at Oric Pharmaceuticals in South San Francisco, CA. His primary expertise is in oral drug delivery. He holds over 18 years of pharmaceutical industry experience in the development of oral dosage forms and drug delivery platforms. Previously he worked as a Principal Scientist at Genentech, Inc. and Bristol-Myers Squibb, Co. (BMS) in New Brunswick, NJ in the Drug Product Science & Technology Department. In addition to BMS, he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) and Morton Grove Pharmaceuticals (currently, Wockhardt USA). He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutical Sciences from Banaras Hindu University, India and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN. He currently serves the Excipient Focus Group chair-elect for the American Association of Pharmaceutical Scientists (AAPS), Adjunct Faculty for the UTHSC, and Associate Faculty for the University of Phoenix, AZ. His current research interests include innovations in dosage form development and drug delivery technologies that enable pharmaceutical development of challenging molecules to resolve stability, pharmacokinetic, and pharmacodynamic issues. He has more than 40 publications and three pending patent applications and has contributed to the development of several marketed drug products.Virender Kumar is an assistant professor of Pharmaceutics in the College of Pharmacy and Pharmaceutical Sciences at the University of Toledo Medical Center. He worked as a Research Assistant Professor and as a postdoctoral at the University of Nebraska Medical Center, Omaha. He received his PhD in Drug Delivery also from the UNMC. He worked as a scientist in A&Z Pharmaceuticals, New York, NY. He received a master in industrial pharmacy from Saint Johns’ University, NY. He also received M. Pharm, and B. Pharm from Guru Jambheshwar University, Hisar, Haryana, India. He has published 43 papers, 6 book chapters, holds 1 US patent, and has edited/written 1 book and two journal issues.

• Section I. Introduction1. Drug discovery2. Drug Development3. Pharmaceutical Considerations4. Biopharmaceutical Considerations5. Pharmacy Math and StatisticsSection II. Physicochemical Principles6. Complexation and Protein Binding7. Chemical Kinetics and Stability8. Interfacial Phenomena9. Colloidal Dispersion10. Surfactants and Micelles11. Pharmaceutical Polymers12. Rheology13. Radiopharmaceuticals14. Drug Delivery Systems15. Organ-specific drug deliverySection III. Dosage Forms16. Suspensions17. Emulsions18. Pharmaceutical Solutions19. Powders and Granules20. Tablets21. Capsules22. Parenteral Dosage Forms23. Semisolid Dosage Forms24. Inserts, Implants, and DevicesSection IV. Pharmaceutical Biotechnology25. Protein- and Peptide-Based Dosage Forms26. Antibody Therapeutics27. Biotechnology-Based Dosage Forms28. Genome editing technologies29. Immunotherapy30. Answers31. Index

Ram I. Mahato is Parke-Davis Endowed Professor and Chairman of the Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE. He was a professor at the University of Tennessee Health Science Center in Memphis, Research Assistant Professor at the University of Utah in Salt Lake City, Senior Scientist at GeneMedicine, Inc., The Woodlands, TX, and as a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He received PhD in Drug Delivery from the University of Strathclyde and BSPS from China Pharmaceutical University. He has published 168 papers, 17 book chapters, holds 4 US patents, and has edited/written 12 books and 14 journal issues (Total Google Citations= 14,609 and h-Index =70). He was a Feature Editor of the Pharmaceutical Research (2006-2013) and Editorial Board Member of eight journals. He is a CRS and AAPS Fellow, Permanent Member of BTSS/NIH Study section, and ASGCT Scientific Advisor. He is applying sound principles in pharmaceutical sciences in the context of the latest advances in life and material sciences to solve challenging drug delivery problems in therapeutics.Ajit S. Narang works as a Vice President at Oric Pharmaceuticals in South San Francisco, CA. His primary expertise is in oral drug delivery. He holds over 18 years of pharmaceutical industry experience in the development of oral dosage forms and drug delivery platforms. Previously he worked as a Principal Scientist at Genentech, Inc. and Bristol-Myers Squibb, Co. (BMS) in New Brunswick, NJ in the Drug Product Science & Technology Department. In addition to BMS, he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) and Morton Grove Pharmaceuticals (currently, Wockhardt USA). He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutical Sciences from Banaras Hindu University, India and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN. He currently serves the Excipient Focus Group chair-elect for the American Association of Pharmaceutical Scientists (AAPS), Adjunct Faculty for the UTHSC, and Associate Faculty for the University of Phoenix, AZ. His current research interests include innovations in dosage form development and drug delivery technologies that enable pharmaceutical development of challenging molecules to resolve stability, pharmacokinetic, and pharmacodynamic issues. He has more than 40 publications and three pending patent applications and has contributed to the development of several marketed drug products.Virender Kumar is an assistant professor of Pharmaceutics in the College of Pharmacy and Pharmaceutical Sciences at the University of Toledo Medical Center. He worked as a Research Assistant Professor and as a postdoctoral at the University of Nebraska Medical Center, Omaha. He received his PhD in Drug Delivery also from the UNMC. He worked as a scientist in A&Z Pharmaceuticals, New York, NY. He received a master in industrial pharmacy from Saint Johns’ University, NY. He also received M. Pharm, and B. Pharm from Guru Jambheshwar University, Hisar, Haryana, India. He has published 43 papers, 6 book chapters, holds 1 US patent, and has edited/written 1 book and two journal issues.

• Section I. Introduction1. Drug discovery2. Drug Development3. Pharmaceutical Considerations4. Biopharmaceutical Considerations5. Pharmacy Math and StatisticsSection II. Physicochemical Principles6. Complexation and Protein Binding7. Chemical Kinetics and Stability8. Interfacial Phenomena9. Colloidal Dispersion10. Surfactants and Micelles11. Pharmaceutical Polymers12. Rheology13. Radiopharmaceuticals14. Drug Delivery Systems15. Organ-specific drug deliverySection III. Dosage Forms16. Suspensions17. Emulsions18. Pharmaceutical Solutions19. Powders and Granules20. Tablets21. Capsules22. Parenteral Dosage Forms23. Semisolid Dosage Forms24. Inserts, Implants, and DevicesSection IV. Pharmaceutical Biotechnology25. Protein- and Peptide-Based Dosage Forms26. Antibody Therapeutics27. Biotechnology-Based Dosage Forms28. Genome editing technologies29. Immunotherapy30. Answers31. Index

Ram I. Mahato is Parke-Davis Endowed Professor and Chairman of the Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE. He was a professor at the University of Tennessee Health Science Center in Memphis, Research Assistant Professor at the University of Utah in Salt Lake City, Senior Scientist at GeneMedicine, Inc., The Woodlands, TX, and as a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He received PhD in Drug Delivery from the University of Strathclyde and BSPS from China Pharmaceutical University. He has published 168 papers, 17 book chapters, holds 4 US patents, and has edited/written 12 books and 14 journal issues (Total Google Citations= 14,609 and h-Index =70). He was a Feature Editor of the Pharmaceutical Research (2006-2013) and Editorial Board Member of eight journals. He is a CRS and AAPS Fellow, Permanent Member of BTSS/NIH Study section, and ASGCT Scientific Advisor. He is applying sound principles in pharmaceutical sciences in the context of the latest advances in life and material sciences to solve challenging drug delivery problems in therapeutics.Ajit S. Narang works as a Vice President at Oric Pharmaceuticals in South San Francisco, CA. His primary expertise is in oral drug delivery. He holds over 18 years of pharmaceutical industry experience in the development of oral dosage forms and drug delivery platforms. Previously he worked as a Principal Scientist at Genentech, Inc. and Bristol-Myers Squibb, Co. (BMS) in New Brunswick, NJ in the Drug Product Science & Technology Department. In addition to BMS, he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) and Morton Grove Pharmaceuticals (currently, Wockhardt USA). He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutical Sciences from Banaras Hindu University, India and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN. He currently serves the Excipient Focus Group chair-elect for the American Association of Pharmaceutical Scientists (AAPS), Adjunct Faculty for the UTHSC, and Associate Faculty for the University of Phoenix, AZ. His current research interests include innovations in dosage form development and drug delivery technologies that enable pharmaceutical development of challenging molecules to resolve stability, pharmacokinetic, and pharmacodynamic issues. He has more than 40 publications and three pending patent applications and has contributed to the development of several marketed drug products.Virender Kumar is an assistant professor of Pharmaceutics in the College of Pharmacy and Pharmaceutical Sciences at the University of Toledo Medical Center. He worked as a Research Assistant Professor and as a postdoctoral at the University of Nebraska Medical Center, Omaha. He received his PhD in Drug Delivery also from the UNMC. He worked as a scientist in A&Z Pharmaceuticals, New York, NY. He received a master in industrial pharmacy from Saint Johns’ University, NY. He also received M. Pharm, and B. Pharm from Guru Jambheshwar University, Hisar, Haryana, India. He has published 43 papers, 6 book chapters, holds 1 US patent, and has edited/written 1 book and two journal issues.

• Section I. Introduction1. Drug discovery2. Drug Development3. Pharmaceutical Considerations4. Biopharmaceutical Considerations5. Pharmacy Math and StatisticsSection II. Physicochemical Principles6. Complexation and Protein Binding7. Chemical Kinetics and Stability8. Interfacial Phenomena9. Colloidal Dispersion10. Surfactants and Micelles11. Pharmaceutical Polymers12. Rheology13. Radiopharmaceuticals14. Drug Delivery Systems15. Organ-specific drug deliverySection III. Dosage Forms16. Suspensions17. Emulsions18. Pharmaceutical Solutions19. Powders and Granules20. Tablets21. Capsules22. Parenteral Dosage Forms23. Semisolid Dosage Forms24. Inserts, Implants, and DevicesSection IV. Pharmaceutical Biotechnology25. Protein- and Peptide-Based Dosage Forms26. Antibody Therapeutics27. Biotechnology-Based Dosage Forms28. Genome editing technologies29. Immunotherapy30. Answers31. Index